- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07928440
Mentalization Orientated Psychoeducation Group for Adult ADHD (MOPAD) (MOPAD)
A Feasibility Study on Mentalization Orientated Psychoeducation Group for Adults With ADHD
Adults with Attention Deficit Hyperactivity Disorder (ADHD)-a neurodevelopmental condition affecting focus, impulse control, and activity levels-often face poor quality of life, emotion management difficulties, and interpersonal challenges. While medication helps core symptoms, it is not always tolerated or fully effective for emotional dysregulation. The National Institute for Health and Care Excellence (NICE) recommends psychological therapies as secondary options, but lacks sufficient evidence to endorse a specific intervention.
The MOPAD study tests whether an introductory Mentalization-Based Treatment (iMBT)-a psychological therapy helping people understand their own and others' mental states-can be delivered in a group format. MBT successfully improves mood and relationship issues in other conditions, offering potential non-drug benefits for adults with ADHD.
This non-randomised interventional feasibility study will recruit 16 adults with diagnosed ADHD. Participants will undertake a 12-week intervention of weekly 100-105 minute group iMBT sessions. Before and after the treatment, participants will complete standardized questionnaires assessing ADHD symptoms, quality of life, emotion regulation, impulsivity, and mentalizing capacity (e.g., ASRS v1.1, CAARS-2, AAQoL, DERS-18, UPPS, MENT-S, RFQ-8), alongside post-study qualitative interviews to share their experiences.
Eligible participants are adults with ADHD recruited from NHS clinical sites. Primary goals are evaluating recruitment (target: 11 participants), retention (target: 70%), safety, therapy fidelity, and patient acceptability. Secondary goals include evaluating clinician feedback and gathering resource data to calculate sample size requirements for a future full-scale trial.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Tayeem Pathan, MBBS MSC
- Telefonní číslo: 0044-01483448020
- E-mail: tayeem.pathan@sabp.nhs.uk
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
• A minimum age of 18 - 65 years at time of consent
- Able to provide written consent with an Informed Consent Form signed by the participant
- Have ADHD as principal diagnosis using following diagnostic instruments. DIVA or ACE under an NHS Neurodevelopmental Service completed within the last 24 months.
- Proficient in spoken English.
Exclusion Criteria:
-
• Comorbidities of antisocial PD, autistic spectrum disorder, schizophrenia spectrum disorder, substance abuse disorder as principal or burdensome diagnosis, at the discretion of the PI.
- On a titrating dose of ADHD or other Psychotropic medication.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Introductory Mentalization based group therapy
Adults with a Diagnosis of ADHD in last two years from a NHS Neurodevelopmental service. |
A psychological therapy helping people understand their own and others' mental state. 12 weeks group intervention. Each session will last 100-105 minutes including 10-15 minutes break. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
This study will examine the feasibility of delivering 12 weekly sessions (90minutes/session plus 10/15 min break in between) of iMBT in a group format to adults with ADHD.
Časové okno: 20 months
|
Recruitment rate : The percentage of participants recruited in the study. It will be considered feasible if 11 out of 16 patients were recruited for the intervention. |
20 months
|
|
This study will examine the feasibility of delivering 12 weekly sessions (90minutes/session plus 10/15 min break in between) of iMBT in a group format to adults with ADHD.
Časové okno: 20 months
|
Attrition rate : The percentage of participants retained in the study. It will be considered feasible if 70% were retained by the end of intervention. |
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
ASRS V1.1 (Adult ADHD self-report scale) :
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
CAARS-2 (Conners Adult ADHD Rating scale)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
AAQoL (Adult ADHD Quality of life)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
DERS-18 (Difficulties in Emotion regulation 18)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
UPPS (Impulsive behaviour scale)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
MENT-S (The mentalization scale)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
RFQ-8 (Reflective function Questionnaire)
|
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
Adverse events (AE) or serious AE during the trial. This will counted in numbers identified through a clear process outlined in protocol. |
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
Fidelity of delivery : Adherence will be measured through supervision of the sessions and report from supervisors. |
20 months
|
|
The study also aims to compare pre and post iMBT group clinical outcome data.
Časové okno: 20 months
|
Acceptability of the intervention to participants: through interview of the participants. Will be reported as themes and quotes from participants. |
20 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Resource outcomes:
Časové okno: 20 months
|
Time taken to recruit participants: Reported in days |
20 months
|
|
Resource outcomes:
Časové okno: 20 months
|
Sample size calculation in number |
20 months
|
|
Resource outcomes:
Časové okno: 20 months
|
Data collection success (percentage of participants completed the outcome measures) |
20 months
|
|
Resource outcomes:
Časové okno: 20 months
|
Initial assessment of the financial resources required to scale the study: reported in number of professionals involved and how much on average they had to offer in hours/week from the onset of recruitment to completion of the trial. |
20 months
|
|
Exploratory endpoints/outcomes
Časové okno: 20 months
|
Participants experience of the intervention |
20 months
|
|
Exploratory endpoints/outcomes
Časové okno: 20 months
|
Facilitators' and Co-facilitators' experience of the intervention. |
20 months
|
Spolupracovníci a vyšetřovatelé
Publikace a užitečné odkazy
Obecné publikace
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. Badoud, D., Rüfenacht, E., Debbané, M., & Perroud, N. (2018). Mentalization-based treatment for adults with attention-deficit/hyperactivity disorder: a pilot study. Research in Psychotherapy: Psychopathology, Process and Outcome, 21(1). Barkley, R. A. (2015). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (4th ed.). Guilford Publications. Bateman, A., & Fonagy, P. (2010). Randomized Controlled Trial of Outpatient Mentalization-Based Treatment Versus Structured Clinical Management for Borderline Personality Disorder. Focus, 8(1), 55-65. Bateman, A., Fonagy, P., Campbell, C., Luyten, P., & Debbané, M. (Eds.). (2023). Cambridge Guide to Mentalization-Based Treatment (MBT). Cambridge University Press. Bora, E., & Pantelis, C. (2016). Meta-analysis of social cognition in attention-deficit/hyperactivity disorder (ADHD): Expectation of deficits relative to controls and comparison with autism spectrum disorder. Psychological Medicine, 46(4), 681-704. Brown, N. M., Flood, T. J., Sarocco, P., Atkins, M. S., & Khachatryan, M. (2017). Social Determinants of Health and ADHD Symptoms in Preschool-Age Children. Journal of Attention Disorders, 26(3), 447-455. Cortese, S., Cinzia, D. G., Chamberlain, S., Philipsen, A., Young, S., Bilbow, A., & Cipriani, A. (2022). Pharmacological and non-pharmacological interventions for adults with ADHD: Protocol for a systematic review and network meta-analysis. BMJ Open, 12(3). https://doi.org/10.1136/bmjopen-2021-058102 Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., ... & Franke, B. (2015). Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1(1), 1-23. Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., ... & Jin, R. (2007). Cross-national prevalence and
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- SABPNHS
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Consent not given
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .